Related Experiment Video
Updated: Aug 16, 2026
Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
Published on: October 13, 2023
Chemokines in human colorectal carcinoma
P K Baier1, S Eggstein, G Wolff-Vorbeck
1University of Freiburg, Department of Surgery, Freiburg, Germany. baier@chir.ukl.uni-freiburg.de
Background:
Chemokines (CKs) may promote antitumor immunity in cancer, act as tumor growth factors, influence metastatic spreading or angiogenesis. The purpose of this study was to investigate whether CK expression is altered in colorectal carcinomas compared to normal mucosa and to elucidate its possible clinico-pathological implications.
Materials And Methods:
The levels of CCL2 (MCP-1), CCL4 (MIP-1beta), CCL5 (RANTES), CXCL 1 (GRO-alpha), CXCL 5 (ENA-78) and CXCL 8 (IL-8) were investigated in 10 colorectal carcinomas and their corresponding normal mucosa by the use of ELISA.
Results:
All CK analyzed, with the exception of CCL5 (RANTES), were expressed at a significantly higher level in malignant tissue.
Conclusion:
Therapeutic studies in colon carcinomas should, therefore, focus more on the neutralization of CKs than on their application.
